Published In
Turkish Journal of Gastroenterology
Volume 30 · Issue Supplement 1
Pages: 59-60
History
Published Online: July 25, 2019
Copyright © 2019 Behice Kurtaran, Figen Sarıgül, Mehmet Çabalak, Sibel Kaya, Nagehan Didem Sarı, Hasan Karsen, Esra Zerdali, Rahmet Güner, Kamuran Türker, Nevin Ince, Fehmi Tabak, Hepcturkey Study Group
Behice Kurtaran
Cukurova University Faculty of Medicine Department of Infectious Diseases Adana Turkey
Figen Sarıgül
Antalya Training and Research Hospital Department of Infectious Diseases Antalya Turkey
Mehmet Çabalak
Mustafa Kemal University Faculty of Medicine Infectious Diseases Department Hatay Turkey
Sibel Kaya
Istanbul University Faculty of Medicine Infectious Diseases Department İstanbul Turkey
Nagehan Didem Sarı
Istanbul Training and Research Hospital Department of Infectious Diseases İstanbul Turkey
Hasan Karsen
Harran University Faculty of Medicine Infectious Diseases Department Şanlıurfa Turkey
Esra Zerdali
Haseki Training and Research Hospital Department of Infectious Diseases İstanbul Turkey
Rahmet Güner
Yıldırım Beyazıt University Faculty of Medicine Infectious Diseases Department Ankara Turkey
Kamuran Türker
Bağcılar Training and Research Hospital Department of Infectious Diseases İstanbul Turkey
Nevin Ince
Düzce University Düzce Turkey
Fehmi Tabak
Istanbul University Faculty of Medicine Infectious Diseases Department İstanbul Turkey
Hepcturkey Study Group
Istanbul University Faculty of Medicine Infectious Diseases Department İstanbul Turkey
Kurtaran, B., Sarıgül, F., Çabalak, M., Kaya, S., Sarı, N. D., Karsen, H., … Group, H. S. (2019). Efficiency and safety of direct acting antivirals in chronic hepatitis C patients ınfected with genotype 2 and 3 in Turkey. Turkish Journal of Gastroenterology, 30(Supplement 1), 59–60. https://doi.org/10.5152/tjg.2019.38
Full Text
PDF
PDF
Abstract
INTRODUCTION: Genotypes 2 and 3 chronic hepatitis C (CHC) patients are less frequently seen than genotype 1 in Turkey. While these genotypes have had favorable treatment outcomes with interferon-based regimens, response rates are lower with direct acting antivirals (DAAs). We aimed to evaluate efficiency and safety of DAAs in CHC patients infected with genotype 2 and 3.
METHODS: Between April 2017 and September 2018, 37 centers recorded 2230 patients. All patients >18 years with CHC under DAAs were enrolled in this observational study. Those infected with genotype 2 and 3 were analyzed for end of treatment response (EoTR) and response at week 12 (SVR12).
RESULTS: Among 2230 patients recorded into the database; 267 (12%) were infected with genotype 2 or 3, 73 (27%) were female and mean age was 41.7±17 years (range 18-84 years). The genotypes were 3 in 189 (71%) and 2 in 78 (29%). 25 (9.4%) had cirrhosis; 24 had compensated (Child-Pugh A) and 1 had decompensated (Child-Pugh B-C) cirrhosis. Liver biopsy was available in 151 (57%, G3: 107, G2: 44) patients; mean histologic activity index (HAI) was 7.4 and fibrosis score was 2.4. HAI was mild (1-6) in 37%, moderate (7-12) in 59%, and severe (13-18) in 4%. Fibrosis was mild in 49%, moderate in 47%, and advanced in 4%. While 200 (79%) patients were treatment-naive, 57 (21%) were previously treated with pegylated interferon+ribavirin: 74% relapse and 26% non-responder. Baseline viral load was 5.3x106 copies/mL. Ledipasvir + Sofosbuvir, Ledipasvir + Sofosbuvir + Ribavirin and Sofosbuvir + Ribavirin were given to 8, 15, and 154 patients, respectively. The drugs were tolerated well. Severe adverse events were not reported. SVR was evaluated in 134 patients, shown in Table 1. Response rate at week 4 was 119/147 (81%), EoTR 143/144 (%99.3%) and SVR12 128/134 (95.5%).
CONCLUSION: This study represents the largest study of genotypes 2 and 3 CHC in Turkey. Genotype 3 is much commoner than genotype 2 (71% vs 29%). Rate of male gender was higher (73%) and mean age was 42 years. Liver histology showed moderate to higher activity in more than half of the patients and fibrosis was moderate to severe in half. Sofosbuvir and ribavirin containing regimens provided a SVR of more than 90%. The response rate in genotype 2 (94%) was lower than that in genotype 3 (96.5%). DAAs containing sofosbuvir and ribavirin have found efficient and safe among genotype 2 and 3 CHC patients in Turkey.
*This study was supported by Gilead Sciences İlaç Ltd. Şti. (İstanbul, Turkey). Company was not involved to the content of the study/publication; no involvement to the decision to submit for publication.
Most read articles by the same author(s)
- Tansu Yamazhan, Esra Zerdali, Yusuf Önlen, Selma Tosun, Özgür Günal, Ayşe Batırel, İmran Hasanoğlu, Tuba Turunç, Umay Balcı, Sibel Yıldız Kaya, Oğuz Karabay, İlknur Esen Yıldız, Lütfiye Nilsun Altunal, Hacer Deniz Özkaya, Selçuk Kaya, Ayşe İnci, Sevil Alkan, Dilek Sevgi Yıldız, Tayibe Bal, Esma Aslıhan Aydemir, Nurullah Eser, Serhat Uysal, Oğuzhan Acet, Fehmi Tabak, Rahmet Güner, A National Multicenter Study on Initial Antiviral Treatment Preferences on Chronic Hepatitis B: Entecavir Versus Tenofovir Disoproxil Fumarate , Turkish Journal of Gastroenterology: Vol. 37 No. 2 (2026): Turkish Journal of Gastroenterology
- Yusuf Önlen, Tayibe Bal, Mehmet Çabalak, Nefise Çuvalcı Öztoprak, Nagehan Didem Sarı, Behice Kurtaran, Ebubekir Şenateş, Alper Gündüz, Esra Zerdali, Hasan Karsen, Ayşe Batırel, Rıdvan Karaali, Rahmet Güner, Tansu Yamazhan, Şükran Köse, Nurettin Erben, Nevin İnce, İftihar Köksal, Figen Sarıgül Yıldırım, Gülşen Yörük, Süheyla Kömür, Sibel Kaya, Şaban Esen, Özgür Günal, İlknur Esen Yıldız, Dilara İnan, Şener Barut, Mustafa Namıduru, Selma Tosun, Kamuran Türker, Alper Şener, Kenan Hızel, Nurcan Baykam, Fazilet Duygu, Esragül Akıncı, Güray Can, Ülkü User, Hanefi Cem Gül, Ayhan Akbulut, Güven Çelebi, Mahmut Sünnetçioğlu, Oğuz Karabay, Hayat Kumbasar Karaosmanoğlu, Fatma Sırmatel, Fehmi Tabak, Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey , Turkish Journal of Gastroenterology: Vol. 33 No. 10 (2022): Turkish Journal of Gastroenterology
- Fehmi Tabak, Cihan Yurdaydın, Sabahattin Kaymakoğlu, Mesut Akarsu, Esra G. Akıncı, Hikmet Akkız, Canan Alkım, Ayhan H. Çekin, Nefise Ö. Çuvalcı, Kadir Demir, Bülent Değertekin, İlyas Dökmetaş, Galip Ersöz, Kenan Hizel, Fatma Ö. Kandemir, Yusuf Önlen, Abdullah Sonsuz, Ebubekir Şenateş, Selma Tosun, Nurdan Tözün, Ramazan Idilman, and Viral Hepatisis Guideline Study Group, Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines , Turkish Journal of Gastroenterology: Vol. 28 No. 2 (2017): Turkish Journal of Gastroenterology
- Sabahattin Kaymakoğlu, İftihar Köksal, Fehmi Tabak, Ulus S. Akarca, Ayhan Akbulut, Filiz Akyüz, Hürrem Bodur, Atahan Çağatay, Dinç Dinçer, Şaban Esen, Rahmet Güner, Selim Gürel, Şükran Köse, Ömer Şentürk, Halis Şimşek, Tansu Yamazhan, Yusuf Yılmaz, Ramazan Idilman, and Viral Hepatisis Guideline Study Group, Recommendation for treatment of hepatitis C virus infection , Turkish Journal of Gastroenterology: Vol. 28 No. 2 (2017): Turkish Journal of Gastroenterology
- Alper Gunduz, Nefise Çuvalcı Öztoprak, Nagehan Didem Sarı, Behice Kurtaran, Yusuf Önlen, Ebubekir Senates, Esra Zerdali, Hasan Karsen, Ayse Batırel, Rıdvan Kara Ali, Rahmet Güner, Tansu Yamazhan, Sukran Kose, Nurettin Erben, Nevin Ince, İftihar Köksal, Figen Sarıgül Yıldırım, Gulsen Yoruk, Suheyla Komur, Tayibe Bal, Sibel Kaya, Şaban Esen, Özgür Günal, Ilknur Esen Yıldız, Dilara Inan, Şener Barut, Mustafa Namıduru, Selma Tosun, Kamuran Türker, Alper Sener, Kenan Hızel, Nurcan Baykam, Fazilet Duygu, Esragül Akıncı, Güray Can, Ulku User, Hanefi Cem Gül, Ayhan Akbulut, Güven Çelebi, Mahmut Sünnetçioğlu, Oğuz Karabay, Hayat Kumbasar Karaosmanoğlu, Fatma Sırmatel, Fehmi Tabak, Efficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye , Turkish Journal of Gastroenterology: Vol. 37 No. 6 (2026): Turkish Journal of Gastroenterology
- Cihan Yurdaydın, Fehmi Tabak, Sabahattin Kaymakoğlu, Mesut Akarsu, Esra G. Akıncı, Hikmet Akkız, Canan Alkım, Ayhan H. Çekin, Nefise Ö. Çuvalcı, Kadir Demir, Bülent Değertekin, İlyas Dökmetaş, Galip Ersöz, Kenan Hizel, Fatma Ö. Kandemir, Yusuf Önlen, Abdullah Sonsuz, Ebubekir Şenateş, Selma Tosun, Nurdan Tözün, Ramazan Idilman, and Viral Hepatisis Guideline Study Group, Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017 Clinical Practice Guidelines , Turkish Journal of Gastroenterology: Vol. 28 No. 2 (2017): Turkish Journal of Gastroenterology
- Ramazan Idilman, Nurcan Baykam, Sabahattin Kaymakoğlu, Fehmi Tabak, Halil İ. Bahçecioğlu, Ahmet Bektaş, Cemal Bulut, Fulya Günşar, Dilara İnan, Hayat K. Karaosmanoğlu, Zeki Karasu, Ferit Kuşçu, Birgül Mete, Ömer Özbakır, Osman C. Özdoğan, Mehmet Parlak, Fatma Sırmatel, Ömer Topalak, Belkis Ünsal, and Viral Hepatisis Guideline Study Group, Turkey 2017 Clinical Practice Guidelines on recommendations for screning diagnosing and managing hepatitis C virus , Turkish Journal of Gastroenterology: Vol. 28 No. 2 (2017): Turkish Journal of Gastroenterology
- Sibel Yıldız Kaya, Behice Kurtaran, Nefise Öztoprak Çuvalcı, Yusuf Önlen, Mehmet Reşat Ceylan, Esra Zerdali, Nagehan Didem Sarı, Ahsen Öncül, Nurettin Erben, Ayse Batirel, Dilara İnan, Süheyla Kömür, Figen Sarıgül Yıldırım, Hasibullah Yaqoobi, Ferit Kuscu, Rahmet Guner, Fehmi Tabak, Hep-C Türkiye Study Group, Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3 , Turkish Journal of Gastroenterology: Vol. 37 No. 1 (2026): Turkish Journal of Gastroenterology
- Bilgehan Aygen, Ahmet Muzaffer Demir, Mahmut Gümüş, Oğuz Karabay, Sabahattin Kaymakoğlu, Aydın Şeref Köksal, İftihar Köksal, Necati Örmeci, Fehmi Tabak, Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report , Turkish Journal of Gastroenterology: Vol. 29 No. 3 (2018): Turkish Journal of Gastroenterology
- Necati Örmeci, Murat Taner Gülşen, Orhan Sezgin, Sevda Aghayeva, Mehmet Demir, Iftihar Köksal, Rahmet Güner, Elife Erarslan, Özgün Ömer Asiller, Ayhan Balkan, Serkan Yaraş, Aysun Çalışkan Kartal, Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region , Turkish Journal of Gastroenterology: Vol. 31 No. 2 (2020): Turkish Journal of Gastroenterology
Article Info
Published In
Journal
Turkish Journal of Gastroenterology
Volume / Issue
Volume 30 · Issue Supplement 1
Pages
59-60
History
Published Online
July 25, 2019
Copyright
Copyright (c) 2019 Behice Kurtaran, Figen Sarıgül, Mehmet Çabalak, Sibel Kaya, Nagehan Didem Sarı, Hasan Karsen, Esra Zerdali, Rahmet Güner, Kamuran Türker, Nevin Ince, Fehmi Tabak, Hepcturkey Study Group
Affiliations
Behice Kurtaran
Cukurova University Faculty of Medicine Department of Infectious Diseases Adana Turkey
Figen Sarıgül
Antalya Training and Research Hospital Department of Infectious Diseases Antalya Turkey
Mehmet Çabalak
Mustafa Kemal University Faculty of Medicine Infectious Diseases Department Hatay Turkey
Sibel Kaya
Istanbul University Faculty of Medicine Infectious Diseases Department İstanbul Turkey
Nagehan Didem Sarı
Istanbul Training and Research Hospital Department of Infectious Diseases İstanbul Turkey
Hasan Karsen
Harran University Faculty of Medicine Infectious Diseases Department Şanlıurfa Turkey
Esra Zerdali
Haseki Training and Research Hospital Department of Infectious Diseases İstanbul Turkey
Rahmet Güner
Yıldırım Beyazıt University Faculty of Medicine Infectious Diseases Department Ankara Turkey
Kamuran Türker
Bağcılar Training and Research Hospital Department of Infectious Diseases İstanbul Turkey
Nevin Ince
Düzce University Düzce Turkey
Fehmi Tabak
Istanbul University Faculty of Medicine Infectious Diseases Department İstanbul Turkey
Hepcturkey Study Group
Istanbul University Faculty of Medicine Infectious Diseases Department İstanbul Turkey
Cite this Article
Kurtaran, B., Sarıgül, F., Çabalak, M., Kaya, S., Sarı, N. D., Karsen, H., … Group, H. S. (2019). Efficiency and safety of direct acting antivirals in chronic hepatitis C patients ınfected with genotype 2 and 3 in Turkey. Turkish Journal of Gastroenterology, 30(Supplement 1), 59–60. https://doi.org/10.5152/tjg.2019.38
Outlines